In hematological malignancies, for example, TGFβ signaling has been studied as a therapeutic target to treat the ineffective erythropoiesis in lower risk myelodysplastic syndromes (LR-MDS) patients10. This evidence concerns the gene TGFB1 and hematologic disorder.